Overview
- The FDA cleared the Wegovy pill for chronic weight management, weight maintenance and reducing major cardiovascular events in eligible adults.
- Novo Nordisk says U.S. availability begins in early January 2026, with the 1.5 mg starter dose priced at $149 per month through select pharmacies and telehealth channels, including TrumpRx, while pricing for higher doses and insurer coverage remain unspecified.
- In late‑stage OASIS-4 testing, the approved 25 mg daily dose produced average weight loss around 14% across all participants and about 16.6% among those adhering to treatment, with mostly gastrointestinal side effects and roughly 7% discontinuation reported in trials.
- The oral formulation requires morning dosing on an empty stomach with a small amount of water and a 30‑minute wait before food or other medicines, and it will be offered in 1.5 mg, 4 mg, 9 mg and 25 mg strengths.
- Eli Lilly’s competing pill, orforglipron, is under FDA review and expected soon, with trial data suggesting slightly lower weight‑loss efficacy but fewer dosing restrictions; both companies pursued expedited U.S. review pathways.